Gilead – media

Safer HIV drugs taken off the shelf by Gilead

It has been stated by the patients that Gilead concealed crucial information that the TDF drugs could trigger kidney and bone risks. A safer alternative in the form of TAF could have been incorporated while marketing Truvada and Atripla. The research into TAF was deliberately stopped and the drugs are not likely to be brought to the shelf in the near future.
- Source: drugdu
- 868
- May 11, 2018
Company Insights Gilead HIV
Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease

Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.
- Source: drugdeliverybusiness
- 641
- May 2, 2018
Gilead Market Views rheumatoid arthritis
Gilead links with Sangamo in gene therapy alliance

Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
- Source: drugdu
- 554
- February 26, 2018
cancer engineered cell therapies Gilead Market Views
J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK

A couple of months after posting positive late-stage data for its quadruplet-in-one-pill for quelling HIV, J&J says it’s filed a marketing application with the FDA ahead of a planned marketing campaign.
- Source: Endpts
- 563
- September 27, 2017
FDA Gilead GSK HIV J&J Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.